Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial
Journal
Cancer
Journal Volume
128
Journal Issue
24
Date Issued
2022-12-15
Author(s)
Brose, Marcia S
Robinson, Bruce G
Sherman, Steven I
Jarzab, Barbara
Vaisman, Fernanda
Hoff, Ana O
Hitre, Erika
Bowles, Daniel W
Sen, Suvajit
Oliver, Jennifer W
Banerjee, Kamalika
Keam, Bhumsuk
Capdevila, Jaume
Abstract
At an interim analysis (median follow-up, 6.2 months; n = 187), the phase 3 COSMIC-311 trial met the primary end point of progression-free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs. 1.9 months; p < .0001) in patients with previously treated radioiodine-refractory differentiated thyroid cancer (RAIR-DTC). The results from an exploratory analysis using an extended datacut are presented.
Subjects
COSMIC-311; cabozantinib; differentiated thyroid cancer; phase 3; placebo; tyrosine kinase inhibitor
SDGs
Type
journal article